Gilead's HIV Prevention Drug Could Be Manufactured At Shocking Low Cost: Report

Gilead Sciences Inc (NASDAQ:GILD) is facing mounting pressure to price its long-acting HIV prevention drug, lenacapavir, affordably as it prepares for U.S. regulatory approval on June 19.

In December 2022, the FDA approved Lenacapavir in combination with other antiretrovirals to treat HIV-1 infection in heavily treatment-experienced adults with multi-drug resistant HIV-1 infection.

Researchers and global health leaders are urging the company to ensure widespread access, especially in low- and middle-income countries, given the drug’s potential to significantly curb the HIV pandemic.

Also Read: Gilead’s HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug

In June 2024, Gilead Sciences shared topline results from an interim analysis of its Phase 3 PURPOSE 1 trial, indicating its twice-yearly lenacapavir demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women, marking a major shift from daily ...